Frontiers in Oncology (Aug 2020)

Somatic BRCA Mutation in a Cholangiocarcinoma Patient for HBOC Syndrome Detection

  • Angelo Virgilio Paradiso,
  • Angelo Virgilio Paradiso,
  • Margherita Patruno,
  • Maria Digennaro,
  • Stefania Tommasi,
  • Brunella Pilato,
  • Antonella Argentiero,
  • Oronzo Brunetti,
  • Nicola Silvestris,
  • Nicola Silvestris

DOI
https://doi.org/10.3389/fonc.2020.01292
Journal volume & issue
Vol. 10

Abstract

Read online

BRCA-associated hereditary breast and ovarian cancer syndrome (HBOC) is characterized by an increased risk of developing other malignancies including cholangiocarcinoma (CCA). Somatic BRCA mutations have been reported in CCA, but they have yet to be utilized in a proband case to identify HBOC in families. Two healthy daughters of a deceased female patient who had had metachronous breast cancer and CCA received genetic counseling to assess their cancer risk. Somatic BRCA1/2 mutation analysis was performed by next-generation sequencing on the DNA extracted from a formalin-fixed, paraffin-embedded CCA biopsy specimen of their mother. A pathogenic variant was identified (c.6468_6469delTC in a BRCA2 gene mutation). Germline BRCA mutation analysis of the two daughters detected the same pathogenic variant in one of them. For the first time, a CCA somatic BRCA mutation has been used to identify a family with HBOC.

Keywords